Cencora announced a major expansion of its third‑party logistics (3PL) network, adding a 500,000‑square‑foot facility in Texas that will be fully operational by 2028 and a dedicated cryogenic unit in the Netherlands. The company also expanded refrigerated and frozen storage in France, further bolstering its cold‑chain capabilities across the United States and Europe.
The Texas facility will triple Cencora’s U.S. capacity for temperature‑sensitive products such as cell and gene therapies, positioning the company to serve the rapidly growing specialty‑drug market. In Europe, the integration of NextPharma Logistics’ existing facilities in Germany, Austria and Switzerland provides immediate access to high‑quality storage and distribution assets, while a new 3PL site is slated to open in Italy in 2026.
By consolidating its logistics operations, Cencora aims to offer manufacturers a single partner for distribution, serialization, quality assurance and compliance management. The expanded network enhances the company’s ability to support advanced therapies from launch to market, giving it a competitive edge over rivals like McKesson and Cardinal Health.
"Our customers trust us to serve as an extension of their operations," said Chris Williams, Senior Vice President and President of Alloga Europe &ICS. "By investing across our 3PL network, we deliver enhanced support tailored to their needs, enabling seamless expansion into new markets and ensuring products are delivered on time and in the right condition."
"Pharmaceutical companies increasingly seek partners that can provide comprehensive support across multiple markets," added Alina Chesnokova, Vice President of Global 3PL Commercialization. "Our internationally scaled 3PL service and suite of commercialization solutions uniquely position us to support their needs and drive growth in the specialty‑drug sector."
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.